Matthew Maxwell Donley net worth and biography

Matthew Donley Biography and Net Worth

Matthew Maxwell Donley is Executive VP-Internal Operations & Strategy at Aurinia Pharmaceuticals, Inc.

Mr. Donley previously occupied the position of Director-Human Resources & Development at Bed Bath & Beyond, Inc., Executive VP-Global Human Resources, IT & Strategy at Sucampo Pharmaceuticals, Inc., Head-Investor Relations & Corporate Communications at Achillion Pharmaceuticals, Inc., Executive Vice President-Human Resources of MedImmune LLC and Member of Society for Human Resource Management.

Matthew Maxwell Donley received a graduate degree and an MBA from George Mason University and an undergraduate degree from the University of Michigan.

What is Matthew Maxwell Donley's net worth?: The estimated net worth of Matthew Maxwell Donley is at least $6.30 million as of March 3rd, 2025. Mr. Donley owns 739,456 shares of Aurinia Pharmaceuticals stock worth more than $6,300,165 as of March 26th. This net worth evaluation does not reflect any other assets that Mr. Donley may own. Additionally, Mr. Donley receives an annual salary of $901,840.00 as VP at Aurinia Pharmaceuticals. Learn More about Matthew Maxwell Donley's net worth.
How old is Matthew Maxwell Donley?: Mr. Donley is currently 55 years old. There are 5 older executives and no younger executives at Aurinia Pharmaceuticals. The oldest executive at Aurinia Pharmaceuticals is Mr. Scott Habig, Chief Commercial Officer, who is 64 years old. Learn More on Matthew Maxwell Donley's age.
What is Matthew Maxwell Donley's salary?: As the VP of Aurinia Pharmaceuticals Inc., Mr. Donley earns $901,840.00 per year. The highest earning executive at Aurinia Pharmaceuticals is Mr. Peter S. Greenleaf M.B.A., President, CEO & Director, who commands a salary of $1,570,000.00 per year. Learn More on Matthew Maxwell Donley's salary.
How do I contact Matthew Maxwell Donley?: The corporate mailing address for Mr. Donley and other Aurinia Pharmaceuticals executives is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. Aurinia Pharmaceuticals can also be reached via phone at 250-708-4272 and via email at ir@auriniapharma.com. Learn More on Matthew Maxwell Donley's contact information.
Has Matthew Maxwell Donley been buying or selling shares of Aurinia Pharmaceuticals?: In the last ninety days, Matthew Maxwell Donley has sold $527,216.00 of Aurinia Pharmaceuticals stock. Most recently, Matthew Maxwell Donley sold 65,902 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a transaction totalling $527,216.00. Following the completion of the sale, the chief operating officer now directly owns 739,456 shares of the company's stock, valued at $5,915,648. Learn More on Matthew Maxwell Donley's trading history.
Who are Aurinia Pharmaceuticals' active insiders?: Aurinia Pharmaceuticals' insider roster includes Matthew Donley (VP), Peter Greenleaf (CEO), Robert Huizinga (EVP), Jill Leversage (Director), Michael Martin (Insider), Joseph Miller (CFO), and Neil Solomons (Insider). Learn More on Aurinia Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Aurinia Pharmaceuticals?: In the last twelve months, insiders at the biotechnology company sold shares 7 times. They sold a total of 366,704 shares worth more than $2,888,411.85. The most recent insider tranaction occured on March, 7th when insider Greg Keenan sold 8,305 shares worth more than $68,350.15. Insiders at Aurinia Pharmaceuticals own 4.3% of the company. Learn More about insider trades at Aurinia Pharmaceuticals.
Information on this page was last updated on 3/7/2025.

Matthew Maxwell Donley Insider Trading History at Aurinia Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/3/2025	Sell	65,902	$8.00	$527,216.00	739,456
5/11/2021	Buy	9,900	$10.07	$99,693.00	9,900

Matthew Maxwell Donley Buying and Selling Activity at Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Company Overview

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Today's Range

Now: $8.52

$8.37

$8.73

50 Day Range

MA: $8.05

$7.55

$8.67

2 Week Range

Now: $8.52

$4.71

$10.67

Volume

1,265,135 shs

Average Volume

1,329,659 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Matthew Donley Biography and Net Worth

What is Matthew Maxwell Donley's net worth?

How old is Matthew Maxwell Donley?

What is Matthew Maxwell Donley's salary?

How do I contact Matthew Maxwell Donley?

Has Matthew Maxwell Donley been buying or selling shares of Aurinia Pharmaceuticals?

Who are Aurinia Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Aurinia Pharmaceuticals?